第五章 討論
第三節 研究限制
針對本研究不盡完善之處，提出下列限制與未來研究改善的建議：
一、理論架構方面
本研究所應用之健康信念模式主要是針對「自身」的基本人口特 質及對相關健康信念的態度來預測是否會採取某些健康行為。本研究 受訪對象為父母，由父母自身的健康信念用來預測替他人（女兒）選 擇健康行為的意願，與傳統的健康信念模式理論略有不同。
二、抽樣方法方面
本研究雖為全國性調查，但考量到研究可行性採用分層集群抽 樣，且為提高問卷回收率增加代表性，透過學校老師發放及回收問 卷，但抽樣學校是否同意，班級老師是否積極配合等因素，都會影響 研究樣本是否隨機分配。
三、資料收集方面
本研究目的之一是調查父母對於HPV 相關的基本知識，爲避免父 母因問卷難度高無法填答而影響問卷的有效性，在完成第一部份HPV 的知識調查後，附上「子宮頸癌、人類乳突病毒及HPV 疫苗」的衛 教說明，或許有的父母會在看完衛教說明後更正HPV 知識的答案，
因此推論本研究有高估父母HPV 相關知識的可能性。另外問卷是透 過學生轉交，也不能排除部分問卷是由學生自行填寫的可能。
參考文獻
ㄧ、英文部分
Adams, M., Jasani, B., & Fiander, A. Human papilloma virus (HPV) prophylactic vaccination: challenges for public health and implications for screening. Vaccine 2007; 25(16): 3007-3013.
Austin, L. T., Ahmad, F., McNally, M. J., & Stewart, D. E. Breast and cervical cancer screening in Hispanic women: a literature review using the health belief model.
Womens Health Issues 2002; 12(3): 122-128.
Bandura: A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev 1977; 84(2): 191-215.
Booth, R. E., Zhang, Y., & Kwiatkowski, C. F. The challenge of changing drug and sex risk behaviors of runaway and homeless adolescents. Child Abuse Negl 1999;
23(12): 1295-1306.
Brewer, N. T., & Fazekas, K. I. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45: 107-114.
Burk, R. D., Kelly, P., Feldman, J., Bromberg, J., Vermund, S. H., DeHovitz, J. A., et al. Declining prevalence of cervicovaginal human papillomavirus infection with age is independent of other risk factors. Sex Transm Dis 1996; 23(4): 333-341.
Cates, W., Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. American Social Health Association Panel. Sex Transm Dis 1999; 26(4 Suppl): S2-7.
Chan, S. S., Cheung, T. H., Lo, W. K., & Chung, T. K. Women's attitudes on human papillomavirus vaccination to their daughters. J Adolesc Health 2007; 41(2):
204-207.
Chen, C. J., Viscidi, R. P., Chuang, C. H., Huang, Y. C., Chiu, C. H., & Lin, T. Y.
Seroprevalence of human papillomavirus types 16 and 18 in the general population in Taiwan: implication for optimal age of human papillomavirus vaccination. J Clin Virol 2007; 38(2): 126-130.
Clifford, G. M., Rana, R. K., Franceschi, S., Smith, J. S., Gough, G., & Pimenta, J. M.
Human papillomavirus genotype distribution in low-grade cervical lesions:
comparison by geographic region and with cervical cancer. Cancer Epidemiol
Biomarkers Prev 2005; 14(5): 1157-1164.
Clifford, G. M., Smith, J. S., Plummer, M., Munoz, N., & Franceschi, S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003; 88(1): 63-73.
Constantine, N. A., & Jerman, P. Acceptance of human papillomavirus vaccination among Californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007; 40(2): 108-115.
Davis, K., Dickman, E. D., Ferris, D., & Dias, J. K. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004; 8(3): 188-194.
Dempsey, A. F., Zimet, G. D., Davis, R. L., & Koutsky, L. Factors that are associated with parental acceptance of human papillomavirus vaccines: a randomized intervention study of written information about HPV. Pediatrics 2006; 117(5):
1486-1493.
Doorbar, J. The papillomavirus life cycle. J Clin Virol 2005; 32 Suppl 1: S7-15.
Ferris, D. G., Waller, J. L., Owen, A., & Smith, J. Midadult women's attitudes about receiving the prophylactic human papillomavirus vaccine. J Low Genit Tract Dis 2007; 11(3): 166-172.
Franco, E. L., & Harper, D. M. Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control. Vaccine 2005; 23: 2388-2394.
Frazer, I. H. Prevention of cervical cancer through papillomavirus vaccination. Nat Rev Immunol 2004; 4(1): 46-54.
Frazer, I. H., & Cox, J. Finding a vaccine for human papillomavirus. Lancet 2006;
367(9528): 2058-2059.
Frazer, I. H., Cox, J. T., Mayeaux, E. J., Jr., Franco, E. L., Moscicki, A. B., Palefsky, J.
M., et al. Advances in prevention of cervical cancer and other human
papillomavirus-related diseases. Pediatr Infect Dis 2006;J, 25(2 Suppl): S65-81, quiz S82.
Fu, H. H., Tsai, H. T., Lin, C. W., & Wei, D. Application of a single sampling plan for auditing medical-claim payments made by Taiwan National Health Insurance.
Health Policy 2004; 70(2): 185-195.
Gerend, M. A., Lee, S. C., & Shepherd, J. E. Predictors of human papillomavirus vaccination acceptability among underserved women. Sex Transm Dis 2007;
34(7): 468-471.
Giannini, S. L., Hanon, E., Moris, P., Van Mechelen, M., Morel, S., Dessy, F., et al.
Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24(33-34): 5937-5949.
Goldie, S. J., Kohli, M., Grima, D., Weinstein, M. C., Wright, T. C., Bosch, F. X., et al.
Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004; 96(8): 604-615.
Harper, D. M., Franco, E. L., Wheeler, C. M., Moscicki, A. B., Romanowski, B., Roteli-Martins, C. M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18:
follow-up from a randomised control trial. Lancet 2006; 367(9518): 1247-1255.
Hildesheim, A., Schiffman, M. H., Gravitt, P. E., Glass, A. G., Greer, C. E., Zhang, T., et al. Persistence of type-specific human papillomavirus infection among
cytologically normal women. J Infect Dis 1994; 169(2): 235-240.
Jansen, K. U., & Shaw, A. R. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004; 55: 319-331.
Janz, N. K., & Becker, M. H. The Health Belief Model: a decade later. Health Educ Q 1984; 11(1): 1-47.
Kahn, J. A., Rosenthal, S. L., Hamann, T., & Bernstein, D. I. Attitudes about human papillomavirus vaccine in young women. Int J STD AIDS 2003; 14(5): 300-306.
Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R., & Schiller, J. T. Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 1992; 89(24): 12180-12184.
Kjaer, S. K., Chackerian, B., van den Brule, A. J., Svare, E. I., Paull, G., Walbomers, J.
M., et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer
Epidemiol Biomarkers Prev 2001; 10(2): 101-106.
Kobayashi, A., Greenblatt, R. M., Anastos, K., Minkoff, H., Massad, L. S., Young, M., et al. Functional attributes of mucosal immunity in cervical intraepithelial
neoplasia and effects of HIV infection. Cancer Res 2004; 64(18): 6766-6774.
Lai, C. H., Huang, H. J., Hsueh, S., Chao, A., Lin, C. T., Huang, S. L., et al. Human papillomavirus genotype in cervical cancer: a population-based study. Int J Cancer 2007; 120(9): 1999-2006.
Lambert, E. C. College students' knowledge of human papillomavirus and
effectiveness of a brief educational intervention. J Am Board Fam Pract 2001;
14(3): 178-183.
Lenselink, C. H., Gerrits, M. M., Melchers, W. J., Massuger, L. F., van Hamont, D., &
Bekkers, R. L. Parental acceptance of Human Papillomavirus vaccines. Eur J Obstet Gynecol Reprod Biol 2008; 137(1): 103-107.
Mahdavi, A., & Monk, B. J. Vaccines against human papillomavirus and cervical cancer: promises and challenges. Oncologist 2005; 10(7): 528-538.
Marlow, L. A., Waller, J., & Wardle, J. Parental attitudes to pre-pubertal HPV vaccination. Vaccine 2007; 25(11): 1945-1952.
Molano, M., Van den Brule, A., Plummer, M., Weiderpass, E., Posso, H., Arslan, A., et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol 2003; 158(5): 486-494.
Munger, K., Baldwin, A., Edwards, K. M., Hayakawa, H., Nguyen, C. L., Owens, M., et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol 2004;
78(21), 11451-11460.
Munoz, N., Bosch, F. X., de Sanjose, S., Herrero, R., Castellsague, X., Shah, K. V., et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348(6): 518-527.
Nakagawa, M., Viscidi, R., Deshmukh, I., Costa, M. D., Palefsky, J. M., Farhat, S., et al. Time course of humoral and cell-mediated immune responses to human papillomavirus type 16 in infected women. Clin Diagn Lab Immunol 2002; 9(4):
877-882.
Newall, A. T., Beutels, P., Wood, J. G., Edmunds, W. J., & MacIntyre, C. R.
Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7(4): 289-296.
Paavonen, J., Jenkins, D., Bosch, F. X., Naud, P., Salmeron, J., Wheeler, C. M., et al.
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369(9580): 2161-2170.
Pagliusi, S. R., & Teresa Aguado, M. Efficacy and other milestones for human papillomavirus vaccine introduction. Vaccine 2004; 23(5): 569-578.
Pitts, M., & Clarke, T. Human papillomavirus infections and risks of cervical cancer:
what do women know? Health Educ Res 2002; 17(6): 706-714.
Roden, R., & Wu, T. C. Preventative and therapeutic vaccines for cervical cancer.
Expert Rev Vaccines 2003; 2(4): 495-516.
Rosenstock, I. M. Historical origins of the health belief model. Health Education Monographs 1974 2(4): 328-335.
Rosenstock, I. M., Strecher, V. J., & Becker, M. H. Social learning theory and the Health Belief Model. Health Educ Q 1988; 15(2): 175-183.
Sanders, G. D., & Taira, A. V. Cost-effectiveness of a potential vaccine for human papillomavirus. Emerg Infect Dis 2003; 9(1): 37-48.
Schiffman, M., & Castle, P. E. Human papillomavirus: epidemiology and public health.
Arch Pathol Lab Med 2003; 127(8): 930-934.
Slomovitz, B. M., Sun, C. C., Frumovitz, M., Soliman, P. T., Schmeler, K. M., Pearson, H. C., et al. Are women ready for the HPV vaccine? Gynecol Oncol 2006; 103(1):
151-154.
Smailbegovic, M. S., Laing, G. J., & Bedford, H. Why do parents decide against immunization? The effect of health beliefs and health professionals. Child Care Health Dev 2003; 29(4): 303-311.
Taira, A. V., Neukermans, C. P., & Sanders, G. D. Evaluating human papillomavirus vaccination programs. Emerg Infect Dis 2004; 10(11): 1915-1923.
Takahashi, O., Noguchi, Y., Rahman, M., Shimbo, T., Goto, M., Matsui, K., et al.
Influence of family on acceptance of influenza vaccination among Japanese patients. Fam Pract 2003; 20(2): 162-166.
Tiro, J. A., Meissner, H. I., Kobrin, S., & Chollette, V. What do women in the U.S.
know about human papillomavirus and cervical cancer? Cancer Epidemiol Biomarkers Prev 2007; 16(2): 288-294.
Tyring, S. K. Human papillomavirus infections: epidemiology, pathogenesis, and host immune response. J Am Acad Dermatol 2000; 43(1 Pt 2): S18-26.
van Essen, G. A., Kuyvenhoven, M. M., & de Melker, R. A. Why do healthy elderly people fail to comply with influenza vaccination? Age Ageing 1997; 26(4):
275-279.
Villa, L. L., Costa, R. L., Petta, C. A., Andrade, R. P., Ault, K. A., Giuliano, A. R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind
placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005; 6(5):
271-278.
Walboomers, J. M., Jacobs, M. V., Manos, M. M., Bosch, F. X., Kummer, J. A., Shah, K. V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189(1): 12-19.
Waller, J., McCaffery, K., Forrest, S., Szarewski, A., Cadman, L., & Wardle, J.
Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003; 79(4): 320-322.
Wang, I. J., Viscidi, R., Hwang, K. C., Lin, T. Y., Chen, C. J., Huang, L. M., et al.
Seroprevalence and risk factors for human papillomavirus in Taiwan. J Trop Pediatr 2008; 54(1): 14-18.
Wang, K. L. Human papillomavirus and vaccination in cervical cancer. Taiwan J Obstet Gynecol 2007; 46(4): 352-362.
WHO. World Health Organization. WHO cancer control program.
2005; http://www.who.int/cancer/en/
Winer, R. L., Lee, S. K., Hughes, J. P., Adam, D. E., Kiviat, N. B., & Koutsky, L. A.
Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157(3): 218-226.
Zimet, G. D., Mays, R. M., Winston, Y., Kee, R., Dickes, J., & Su, L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000;
9(1): 47-50.
二、中文部分
中華民國公共衛生學會癌症登記工作小組網：臺灣女性生殖器癌症年報。2007：
http://crs.cph.ntu.edu.tw/crs_c/index.htm。
行政院衛生署國民健康局：94 年癌症登記年度報告。2007：
http://crs.cph.ntu.edu.tw/crs_c/annual.html。
周碧瑟、賴明芸：各國子宮頸癌篩檢計畫之初探。公共衛生1993；19： 384-392。
官蔚菁、陳清惠、陸偉明：台灣健康信念模式研究之統合分析。國立成功大學碩 士論文，2004。
范光宇、吳穗華、林秀美：台灣省婦女癌症防治計畫七十一至七十五年度子宮頸 癌疑似患者追蹤調查報告。公共衛生1998：14；213-222。
教育部統計處：國民中學概況─國民中學學生人數。2006：
http://www.edu.tw/EDU_WEB/EDU_MGT/STATISTICS。
教育部統計處：國民中學名錄。2007：
http://www.edu.tw/files/site_content/b0013/j1.xls。
陳建仁：人類乳突病毒與婦女健康學術研討會。台北：國際會議廳，2007。
曾志仁：94 年國健局台灣地區人類乳突病毒流行病學計畫，2005a。
曾志仁：HPV Vaccine Recommendations, Advisory Committee on HPV
Immunization Practices of Taiwan Association of Obstetrics and Gynecology OBGYN，2005b。
溫麗芬、張彩秀：應用健康信念模式探討青少女接種子宮頸癌疫苗意向之相關因 素。弘光科技大學碩士論文，2007。
葉樹人、陳慧祺、黃立民：子宮頸癌疫苗。台灣醫學2007；11(6)：649-654。
廖芷嫻、湯澡薰：人類乳突病毒疫苗之經濟價值。臺北醫學大學碩士論文，2007。
劉培懿、王秀紅：婦女感染人類乳突狀病毒之危險因素分析。高雄醫學大學碩士 論文，2004。
衛生署全國衛生統計資訊網：民國94 年國人死因統計結果摘要。2007：
http://www.doh.gov.tw/statistic/data/。
附錄一 專家效度修正前問卷
以下是有關於「子宮頸癌、人類乳突病毒(HPV)及 HPV 疫苗」的介紹，是為了幫助填答問卷的
第二部分、對於「預防接種行為」的相關健康信念
3. 我擔心接種 HPV 疫苗後，我女兒對「性」的
1. 您是否同意並願意自費讓您女兒接種 HPV 疫苗？ 1 2 3 4 明:___________ )
1 2 3 4
附錄二 專家效度審查學者名單
專家效度名單（依姓氏筆畫排列）
李釆娟 現任中國醫藥大學中國醫學研究所教授 美國密西根大學流行病學博士
林隆堯 現任中山醫學大學醫學院院長；
中山醫學大學醫學研究所教授 美國哈佛大學婦幼衛生研究所博士 洪耀欽 現任中國醫藥大學醫醫學系教授﹔
中國醫藥大學附設醫婦癌科主任 日本大阪醫科大學醫學博士
黃光華 現任中國醫藥大學醫務管理研究所助理教授 陽明大學公共衛生研究所衛生政策與管理博士 楊冠洋 現任美國默克藥廠亞太醫學事務處處長；
陽明醫學大學醫務管理研究所兼任副教授 美國哥倫比亞大學流行病學博士
龍紀萱 現任中國醫藥大學醫務管理研究所助理教授 東海大學社會工作系博士
附錄三 正式施測問卷
聯絡電話：04-22053366 轉 6302 傳真電話：04-22028895 電子信箱：[email protected]
第一部分、對於「人類乳突病毒(HPV)」的知識
¾ 醫學界已經證實人類乳突病毒 (HPV) 是引起子宮頸癌的原因。除了子宮頸癌之外，HPV 過，證實它對疫苗保護型別(6、11、16、18 型)病毒所引起的子宮頸癌前病變有 100%的 保護效果。而且 HPV 疫苗的安全性和其它常見的疫苗(例如: B 型肝炎疫苗)一樣高，接種
以下有一些敘述句，請您在看完後，勾選回答您對敘述內容同意的程度
第三部分、對於「人類乳突病毒(HPV)疫苗」的接受度
附錄四 問卷填寫說明
聯絡電話：04-22053366 轉 6302； 傳真電話：04-22028895